Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Damokosh
Andrew Damokosh, West Hartford, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20100009358 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer. | 01-14-2010 |
Andrew I. Damokosh, West Hartford, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20090181393 | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy - The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting. | 07-16-2009 |
Andrew I. Damokosh, West Hortford, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20090136961 | Novel compositions and methods for identification, assessment, prevention, and therapy of ovarian cancer - The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer. | 05-28-2009 |